(SION) Sionna Therapeutics, Common - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.816m USD | Total Return: 216.1% in 12m
Avg Turnover: 14.2M
Warnings
Altman Z'' -15.00 < 1.0 - financial distress zone
Volatile
Tailwinds
Leader
Sionna Therapeutics (SION) is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for cystic fibrosis. The company’s pipeline targets the cystic fibrosis transmembrane conductance regulator (CFTR) protein through multiple mechanisms, including transmembrane domain 1 (TMD1) correctors, potentiators, and nucleotide-binding domain 1 (NBD1) stabilizers. Its lead assets, galicaftor and navocaftor, have recently completed Phase 2 clinical trials.
Operating within the biotechnology sector, Sionna utilizes a high-risk, high-reward business model characterized by heavy research and development spending prior to commercial revenue. The company’s strategy focuses on next-generation CFTR modulation, attempting to improve clinical outcomes for patients who do not achieve full restoration of protein function with existing standard-of-care treatments. Investors can find deeper fundamental metrics and valuation data on ValueRay.
Incorporated in 2019 and headquartered in Waltham, Massachusetts, the firm underwent a name change from Sling Therapeutics in 2021. Its current portfolio includes six distinct compounds ranging from Phase 1 to Phase 2a stages of clinical development.
- Clinical trial data readouts for SION-2222 and SION-719 determine near-term valuation
- Competitive positioning against Vertex Pharmaceuticals dictates long-term market share potential
- Progress of TMD1 and NBD1 combination therapies drives pipeline expansion
- Future capital requirements for late-stage clinical trials influence cash runway and dilution
- Regulatory approval milestones for CFTR correctors act as primary stock price catalysts
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA -8.50 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.24 > 3% & CFO -71.8m > Net Income -85.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.9m) vs 12m ago 1.88% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.69 (Total Current Assets 221.0m - Total Current Liabilities 9.78m) / Total Assets 305.0m |
| B: -0.93 (Retained Earnings -283.1m / Total Assets 305.0m) |
| C: -0.26 (EBIT TTM -88.7m / Avg Total Assets 337.4m) |
| D: -16.82 (Book Value of Equity -283.2m / Total Liabilities 16.8m) |
| Altman-Z'' = -17.92 = D |
As of May 24, 2026, the stock is trading at USD 41.75 with a total of 236,909 shares traded.
Over the past week, the price has changed by +2.26%,
over one month by -4.79%,
over three months by +13.93% and
over the past year by +216.14%.
Sionna Therapeutics, Common has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy SION.
- StrongBuy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 50.5 | 21% |
Revenue TTM = 0.0 USD
EBIT TTM = -88.7m USD
EBITDA TTM = -88.6m USD
Long Term Debt = 7.05m USD (estimated: total debt 8.38m - short term 1.32m)
Short Term Debt = 1.32m USD (from shortTermDebt, last quarter)
Debt = 8.38m USD (from shortLongTermDebtTotal, last quarter) (leases 8.68m already included)
Net Debt = -207.8m USD (calculated: Debt 8.38m - CCE 216.2m)
Enterprise Value = 1.61b USD (1.82b + Debt 8.38m - CCE 216.2m)
Interest Coverage Ratio = unknown (Ebit TTM -88.7m / Interest Expense TTM 0.0)
EV/FCF = -22.29x (Enterprise Value 1.61b / FCF TTM -72.1m)
FCF Yield = -4.49% (FCF TTM -72.1m / Enterprise Value 1.61b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 553k) / Revenue TTM)
Tobins Q-Ratio = 5.27 (Enterprise Value 1.61b / Total Assets 305.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 8.38m)
Taxrate = 21.0% (US default 21%)
NOPAT = -70.1m (EBIT -88.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.60 (Total Current Assets 221.0m / Total Current Liabilities 9.78m)
Debt / Equity = 0.03 (Debt 8.38m / totalStockholderEquity, last quarter 288.2m)
Debt / EBITDA = 2.35 (negative EBITDA) (Net Debt -207.8m / EBITDA -88.6m)
Debt / FCF = 2.88 (negative FCF - burning cash) (Net Debt -207.8m / FCF TTM -72.1m)
Total Stockholder Equity = 313.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.36% (Net Income -85.6m / Total Assets 305.0m)
RoE = -14.35% (Net Income TTM -85.6m / Total Stockholder Equity 596.4m)
RoCE = -14.70% (EBIT -88.7m / Capital Employed (Equity 596.4m + L.T.Debt 7.05m))
RoIC = -28.79% (negative operating profit) (NOPAT -70.1m / Invested Capital 243.5m)
WACC = 10.86% (E(1.82b)/V(1.82b) * Re(10.91%) + D(8.38m)/V(1.82b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.91% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 22.68 | Cagr: 0.80%
[DCF] Fair Price = unknown (Cash Flow -72.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.25 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.64 | Chg30d=-19.50% | Revisions=+0% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.66 | Chg30d=-21.30% | Revisions=-14% | Analysts=8
EPS current Year (2026-12-31): EPS=-2.53 | Chg30d=-14.44% | Revisions=+0% | GrowthEPS=-34.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.85 | Chg30d=-10.26% | Revisions=+11% | GrowthEPS=-12.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -14%